Compare · NTRB vs STE
NTRB vs STE
Side-by-side comparison of Nutriband Inc. (NTRB) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRB and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.50B, about 477.7x NTRB ($42.9M).
- Over the past year, NTRB is down 54.9% and STE is down 12.0% - STE leads by 43.0 points.
- STE has been more active in the news (39 items in the past 4 weeks vs 1 for NTRB).
- STE has more recent analyst coverage (16 ratings vs 1 for NTRB).
- Company
- Nutriband Inc.
- STERIS plc (Ireland)
- Price
- $3.53+2.32%
- $213.78+1.78%
- Market cap
- $42.9M
- $20.50B
- 1M return
- -11.19%
- +3.07%
- 1Y return
- -54.95%
- -11.98%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 39
- Recent ratings
- 1
- 16
Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest NTRB
- Amendment: SEC Form 10-K/A filed by Nutriband Inc.
- Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
- SEC Form 10-K filed by Nutriband Inc.
- Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
- Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
- Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
- Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Nutriband Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 90 units of Ordinary Shares, decreasing direct ownership by 0.68% to 13,184 units (SEC Form 4)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)